| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 75 | 2024 | 4895 | 5.050 |
Why?
|
| Melanoma | 40 | 2024 | 5595 | 2.430 |
Why?
|
| Carcinoma, Merkel Cell | 9 | 2023 | 172 | 2.230 |
Why?
|
| Skin Diseases | 8 | 2021 | 366 | 1.810 |
Why?
|
| Carcinoma, Squamous Cell | 22 | 2024 | 5593 | 1.690 |
Why?
|
| Drug Eruptions | 10 | 2021 | 271 | 1.560 |
Why?
|
| Keratinocytes | 7 | 2018 | 244 | 1.520 |
Why?
|
| Nevus | 5 | 2023 | 116 | 1.240 |
Why?
|
| Melanocytes | 9 | 2021 | 240 | 1.060 |
Why?
|
| Mycosis Fungoides | 7 | 2024 | 341 | 1.010 |
Why?
|
| Biomarkers, Tumor | 26 | 2024 | 10708 | 1.010 |
Why?
|
| Skin | 10 | 2022 | 1271 | 0.960 |
Why?
|
| Conjunctival Neoplasms | 3 | 2024 | 124 | 0.950 |
Why?
|
| Paget's Disease, Mammary | 2 | 2023 | 40 | 0.940 |
Why?
|
| Lichenoid Eruptions | 3 | 2020 | 37 | 0.890 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 2 | 2020 | 107 | 0.810 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 4 | 2024 | 47 | 0.790 |
Why?
|
| Nevus, Pigmented | 3 | 2017 | 116 | 0.770 |
Why?
|
| Eccrine Glands | 1 | 2021 | 5 | 0.770 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2024 | 1097 | 0.750 |
Why?
|
| Vascular Neoplasms | 2 | 2018 | 112 | 0.730 |
Why?
|
| Immunohistochemistry | 26 | 2024 | 7655 | 0.700 |
Why?
|
| Keratoacanthoma | 1 | 2020 | 19 | 0.700 |
Why?
|
| Ear Neoplasms | 2 | 2018 | 64 | 0.690 |
Why?
|
| Diagnosis, Differential | 21 | 2023 | 4831 | 0.690 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 2 | 2010 | 36 | 0.690 |
Why?
|
| Papillomavirus Infections | 4 | 2024 | 999 | 0.680 |
Why?
|
| Dermatology | 2 | 2020 | 72 | 0.670 |
Why?
|
| Hair Follicle | 3 | 2020 | 63 | 0.660 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 232 | 0.650 |
Why?
|
| Head and Neck Neoplasms | 10 | 2023 | 4147 | 0.640 |
Why?
|
| Dendritic Cells | 3 | 2020 | 1110 | 0.640 |
Why?
|
| Vulvar Neoplasms | 2 | 2021 | 235 | 0.640 |
Why?
|
| Epidermis | 5 | 2017 | 196 | 0.640 |
Why?
|
| Carcinoma, Basal Cell | 5 | 2019 | 290 | 0.630 |
Why?
|
| Apocrine Glands | 1 | 2018 | 15 | 0.630 |
Why?
|
| Ear Canal | 1 | 2018 | 31 | 0.620 |
Why?
|
| Cell Differentiation | 9 | 2023 | 4116 | 0.600 |
Why?
|
| Humans | 125 | 2024 | 270740 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2024 | 3409 | 0.570 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2018 | 402 | 0.550 |
Why?
|
| Sweat Gland Neoplasms | 4 | 2024 | 72 | 0.550 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 3 | 2024 | 65 | 0.540 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 550 | 0.530 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2023 | 2313 | 0.520 |
Why?
|
| Hamartoma | 1 | 2016 | 90 | 0.510 |
Why?
|
| Neoplasm Staging | 18 | 2022 | 14012 | 0.500 |
Why?
|
| Leishmania donovani | 1 | 2015 | 24 | 0.500 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2024 | 557 | 0.500 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 414 | 0.500 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2015 | 54 | 0.500 |
Why?
|
| Aged, 80 and over | 35 | 2024 | 30998 | 0.490 |
Why?
|
| Aged | 56 | 2024 | 73333 | 0.490 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2014 | 37 | 0.460 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 1089 | 0.460 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 517 | 0.450 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 1229 | 0.450 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 87 | 0.450 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 691 | 0.450 |
Why?
|
| Isoxazoles | 1 | 2014 | 81 | 0.450 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 722 | 0.450 |
Why?
|
| Male | 70 | 2023 | 128315 | 0.440 |
Why?
|
| Meningioma | 2 | 2017 | 308 | 0.440 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3345 | 0.440 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 1105 | 0.430 |
Why?
|
| Paget Disease, Extramammary | 2 | 2023 | 54 | 0.420 |
Why?
|
| Eyelid Neoplasms | 3 | 2019 | 193 | 0.420 |
Why?
|
| Military Personnel | 1 | 2015 | 233 | 0.420 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2024 | 1335 | 0.410 |
Why?
|
| Morpholines | 1 | 2014 | 296 | 0.410 |
Why?
|
| Meningeal Neoplasms | 2 | 2017 | 473 | 0.400 |
Why?
|
| Ipilimumab | 6 | 2021 | 764 | 0.400 |
Why?
|
| Hematuria | 1 | 2012 | 83 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 7 | 2024 | 4481 | 0.390 |
Why?
|
| Lymphomatoid Papulosis | 2 | 2023 | 67 | 0.390 |
Why?
|
| Nevus, Blue | 2 | 2023 | 40 | 0.390 |
Why?
|
| Poroma | 2 | 2024 | 11 | 0.390 |
Why?
|
| Muscle Weakness | 1 | 2012 | 111 | 0.380 |
Why?
|
| Female | 64 | 2024 | 148940 | 0.380 |
Why?
|
| Middle Aged | 50 | 2023 | 90352 | 0.380 |
Why?
|
| Immunotherapy | 7 | 2024 | 3557 | 0.370 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2024 | 69 | 0.350 |
Why?
|
| Ki-1 Antigen | 3 | 2023 | 186 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 10400 | 0.340 |
Why?
|
| Lymphatic Metastasis | 12 | 2024 | 4963 | 0.340 |
Why?
|
| Carcinoma, Small Cell | 2 | 2023 | 427 | 0.330 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2009 | 22 | 0.330 |
Why?
|
| Telomerase | 2 | 2023 | 547 | 0.320 |
Why?
|
| Epithelial Cells | 3 | 2020 | 1875 | 0.320 |
Why?
|
| Biopsy | 10 | 2023 | 3484 | 0.310 |
Why?
|
| Retrospective Studies | 24 | 2022 | 39890 | 0.310 |
Why?
|
| Adult | 37 | 2024 | 82040 | 0.300 |
Why?
|
| Immunity, Innate | 2 | 2023 | 699 | 0.300 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2020 | 225 | 0.300 |
Why?
|
| Carcinoma | 2 | 2019 | 2610 | 0.300 |
Why?
|
| Prognosis | 17 | 2023 | 22505 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1388 | 0.290 |
Why?
|
| Transcription Factor AP-2 | 1 | 2007 | 78 | 0.290 |
Why?
|
| Ultraviolet Rays | 2 | 2024 | 588 | 0.290 |
Why?
|
| Eyelids | 2 | 2019 | 156 | 0.290 |
Why?
|
| Antineoplastic Agents | 8 | 2021 | 14617 | 0.290 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 4130 | 0.280 |
Why?
|
| Anilides | 2 | 2019 | 295 | 0.270 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2019 | 291 | 0.270 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2016 | 84 | 0.270 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 4960 | 0.260 |
Why?
|
| Scalp | 2 | 2017 | 155 | 0.260 |
Why?
|
| Ki-67 Antigen | 2 | 2018 | 675 | 0.250 |
Why?
|
| Cloning, Molecular | 1 | 2007 | 1430 | 0.250 |
Why?
|
| Staining and Labeling | 2 | 2016 | 445 | 0.240 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2020 | 617 | 0.240 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2021 | 389 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 4048 | 0.230 |
Why?
|
| Nectins | 1 | 2024 | 12 | 0.230 |
Why?
|
| Lymph Nodes | 3 | 2020 | 3077 | 0.230 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 304 | 0.230 |
Why?
|
| Merkel cell polyomavirus | 3 | 2021 | 31 | 0.230 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 719 | 0.220 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2018 | 460 | 0.220 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2023 | 5 | 0.220 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2023 | 9 | 0.220 |
Why?
|
| Pemphigoid, Bullous | 1 | 2023 | 23 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 4 | 2022 | 1336 | 0.210 |
Why?
|
| Endophthalmitis | 1 | 2023 | 82 | 0.210 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2022 | 1458 | 0.210 |
Why?
|
| Tick Bites | 1 | 2022 | 9 | 0.200 |
Why?
|
| Nail Diseases | 1 | 2022 | 39 | 0.200 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2022 | 22 | 0.200 |
Why?
|
| Pseudolymphoma | 1 | 2022 | 22 | 0.200 |
Why?
|
| Argyria | 1 | 2021 | 5 | 0.190 |
Why?
|
| Pyridines | 2 | 2019 | 1313 | 0.190 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 1903 | 0.190 |
Why?
|
| Nails | 1 | 2021 | 36 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2023 | 315 | 0.190 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 62 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2023 | 33737 | 0.180 |
Why?
|
| Repressor Proteins | 3 | 2023 | 1718 | 0.180 |
Why?
|
| Carcinoma, Large Cell | 1 | 2021 | 98 | 0.180 |
Why?
|
| Langerhans Cell Sarcoma | 1 | 2020 | 15 | 0.180 |
Why?
|
| Tertiary Lymphoid Structures | 1 | 2021 | 37 | 0.180 |
Why?
|
| Psoriasis | 1 | 2021 | 143 | 0.180 |
Why?
|
| Disease-Free Survival | 7 | 2023 | 10265 | 0.180 |
Why?
|
| Cicatrix | 1 | 2022 | 187 | 0.180 |
Why?
|
| Exanthema | 1 | 2023 | 212 | 0.180 |
Why?
|
| Pathology, Clinical | 1 | 2021 | 129 | 0.180 |
Why?
|
| GATA3 Transcription Factor | 1 | 2021 | 144 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 172 | 0.170 |
Why?
|
| Education, Distance | 1 | 2021 | 100 | 0.170 |
Why?
|
| Lichen Planus | 1 | 2020 | 22 | 0.170 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 152 | 0.170 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Young Adult | 13 | 2021 | 22251 | 0.170 |
Why?
|
| Metaplasia | 1 | 2021 | 384 | 0.170 |
Why?
|
| DNA Mutational Analysis | 4 | 2022 | 2357 | 0.170 |
Why?
|
| Mitotic Index | 2 | 2016 | 162 | 0.170 |
Why?
|
| Risk Factors | 7 | 2022 | 17888 | 0.170 |
Why?
|
| Manuals as Topic | 1 | 2019 | 18 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 7914 | 0.160 |
Why?
|
| Orbit Evisceration | 1 | 2019 | 47 | 0.160 |
Why?
|
| Carcinosarcoma | 1 | 2020 | 145 | 0.160 |
Why?
|
| Keratitis, Herpetic | 1 | 2019 | 28 | 0.160 |
Why?
|
| Karyopherins | 1 | 2020 | 134 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2023 | 517 | 0.160 |
Why?
|
| Hemangiosarcoma | 2 | 2018 | 238 | 0.160 |
Why?
|
| Elastic Tissue | 1 | 2018 | 35 | 0.160 |
Why?
|
| Lymphatic Vessels | 2 | 2018 | 138 | 0.160 |
Why?
|
| Neoplasm Metastasis | 5 | 2021 | 5315 | 0.160 |
Why?
|
| Sunlight | 1 | 2018 | 80 | 0.160 |
Why?
|
| B7 Antigens | 1 | 2019 | 84 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 417 | 0.150 |
Why?
|
| Radiodermatitis | 1 | 2018 | 79 | 0.150 |
Why?
|
| Xanthomatosis | 1 | 2018 | 22 | 0.150 |
Why?
|
| Organic Chemicals | 1 | 2018 | 103 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 174 | 0.150 |
Why?
|
| Osteonectin | 1 | 2018 | 55 | 0.150 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2018 | 66 | 0.150 |
Why?
|
| Papillomaviridae | 2 | 2022 | 636 | 0.150 |
Why?
|
| Histiocytes | 1 | 2018 | 94 | 0.150 |
Why?
|
| Coccidioidomycosis | 1 | 2018 | 33 | 0.150 |
Why?
|
| Erythema Nodosum | 1 | 2017 | 15 | 0.150 |
Why?
|
| Antigens, Neoplasm | 3 | 2023 | 1580 | 0.150 |
Why?
|
| Sarcoma, Myeloid | 1 | 2018 | 93 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2020 | 878 | 0.150 |
Why?
|
| Chondrosarcoma | 1 | 2020 | 213 | 0.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 331 | 0.150 |
Why?
|
| Receptors, CCR4 | 1 | 2017 | 35 | 0.150 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2018 | 67 | 0.150 |
Why?
|
| Pruritus | 1 | 2018 | 90 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 585 | 0.150 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 141 | 0.140 |
Why?
|
| Panniculitis | 1 | 2017 | 58 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2020 | 7238 | 0.140 |
Why?
|
| Stem Cell Transplantation | 3 | 2023 | 1418 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2018 | 231 | 0.140 |
Why?
|
| Sarcoidosis | 1 | 2018 | 113 | 0.140 |
Why?
|
| Keratin-6 | 2 | 2020 | 40 | 0.140 |
Why?
|
| Keratin-5 | 2 | 2020 | 57 | 0.140 |
Why?
|
| Immune System Diseases | 1 | 2017 | 65 | 0.140 |
Why?
|
| Granuloma | 1 | 2018 | 153 | 0.140 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 5866 | 0.140 |
Why?
|
| Scedosporium | 1 | 2016 | 24 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2016 | 41 | 0.140 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 42 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 1655 | 0.140 |
Why?
|
| Chromosomes, Human, 6-12 and X | 1 | 2016 | 18 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2020 | 1137 | 0.130 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2016 | 24 | 0.130 |
Why?
|
| Saccharomycetales | 1 | 2016 | 47 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2016 | 78 | 0.130 |
Why?
|
| Research | 1 | 2018 | 427 | 0.130 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 485 | 0.130 |
Why?
|
| Mutation | 8 | 2023 | 15912 | 0.130 |
Why?
|
| Warts | 1 | 2015 | 22 | 0.130 |
Why?
|
| Wound Healing | 1 | 2020 | 749 | 0.130 |
Why?
|
| Wilms Tumor | 1 | 2018 | 301 | 0.130 |
Why?
|
| Time Factors | 5 | 2021 | 13006 | 0.130 |
Why?
|
| Homeostasis | 1 | 2020 | 925 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2021 | 705 | 0.120 |
Why?
|
| Afghan Campaign 2001- | 1 | 2015 | 122 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2021 | 6764 | 0.120 |
Why?
|
| Fingers | 1 | 2016 | 130 | 0.120 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 317 | 0.120 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 5101 | 0.120 |
Why?
|
| Calcinosis | 1 | 2018 | 426 | 0.120 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 1002 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1032 | 0.120 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 743 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 1109 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 494 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2023 | 3949 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 1942 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2019 | 1418 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2023 | 6256 | 0.110 |
Why?
|
| Stem Cells | 1 | 2020 | 1216 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 840 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2019 | 2033 | 0.110 |
Why?
|
| Adolescent | 9 | 2021 | 32767 | 0.110 |
Why?
|
| Child, Preschool | 6 | 2021 | 17061 | 0.110 |
Why?
|
| Ear Cartilage | 1 | 2012 | 4 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2021 | 1325 | 0.110 |
Why?
|
| Disease Management | 1 | 2018 | 1090 | 0.110 |
Why?
|
| Endothelial Cells | 1 | 2019 | 1038 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2016 | 314 | 0.110 |
Why?
|
| Ear, External | 1 | 2012 | 44 | 0.100 |
Why?
|
| Mycoses | 1 | 2016 | 393 | 0.100 |
Why?
|
| United States | 6 | 2024 | 15861 | 0.100 |
Why?
|
| Gene Expression | 2 | 2019 | 3640 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2018 | 755 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 1586 | 0.100 |
Why?
|
| Mice, Transgenic | 2 | 2010 | 4223 | 0.100 |
Why?
|
| Mice | 6 | 2020 | 35600 | 0.100 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 12033 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1568 | 0.100 |
Why?
|
| Acitretin | 2 | 2021 | 12 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2020 | 1465 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2017 | 1067 | 0.090 |
Why?
|
| Keratin-10 | 1 | 2010 | 2 | 0.090 |
Why?
|
| Keratin-14 | 1 | 2010 | 24 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1367 | 0.090 |
Why?
|
| Intermediate Filament Proteins | 1 | 2010 | 80 | 0.090 |
Why?
|
| Animals | 8 | 2022 | 61956 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2021 | 2345 | 0.090 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2010 | 183 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2022 | 197 | 0.090 |
Why?
|
| Chromosome Positioning | 1 | 2009 | 7 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 2453 | 0.090 |
Why?
|
| Disease Progression | 4 | 2023 | 6867 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 16215 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 290 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2010 | 249 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2009 | 84 | 0.080 |
Why?
|
| Chromosomes, Human | 1 | 2009 | 288 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 1894 | 0.080 |
Why?
|
| Fatal Outcome | 2 | 2020 | 822 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 427 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1956 | 0.070 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 224 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2018 | 3156 | 0.070 |
Why?
|
| Tetracycline | 1 | 2007 | 106 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 5231 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2024 | 2422 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 15218 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3597 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2017 | 7265 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 16689 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 2 | 2017 | 172 | 0.070 |
Why?
|
| DNA Damage | 1 | 2014 | 1989 | 0.070 |
Why?
|
| Genes, Reporter | 1 | 2007 | 820 | 0.060 |
Why?
|
| Tubular Sweat Gland Adenomas | 1 | 2024 | 2 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2020 | 1608 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2020 | 1379 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 2331 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2010 | 3584 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2471 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 3108 | 0.060 |
Why?
|
| Glia Maturation Factor | 1 | 2024 | 8 | 0.060 |
Why?
|
| Child | 6 | 2021 | 30559 | 0.060 |
Why?
|
| Ethiopia | 1 | 2024 | 29 | 0.060 |
Why?
|
| Neoplasms | 3 | 2021 | 15927 | 0.060 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 2024 | 16 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 1823 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 39 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 2250 | 0.060 |
Why?
|
| Infant | 4 | 2020 | 13999 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2008 | 3216 | 0.060 |
Why?
|
| Phenotype | 3 | 2023 | 6509 | 0.060 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2023 | 35 | 0.060 |
Why?
|
| Cell Line | 2 | 2009 | 5338 | 0.050 |
Why?
|
| PAX5 Transcription Factor | 1 | 2023 | 47 | 0.050 |
Why?
|
| Blister | 1 | 2023 | 30 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2023 | 31 | 0.050 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2023 | 40 | 0.050 |
Why?
|
| SOXC Transcription Factors | 1 | 2023 | 58 | 0.050 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2024 | 100 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2022 | 2062 | 0.050 |
Why?
|
| Carcinoma, Ductal | 1 | 2024 | 144 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2023 | 135 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2021 | 1857 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5694 | 0.050 |
Why?
|
| Conjunctiva | 1 | 2024 | 225 | 0.050 |
Why?
|
| Inclusion Bodies | 1 | 2022 | 87 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2023 | 210 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 3658 | 0.050 |
Why?
|
| Recurrence | 2 | 2020 | 4878 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 3187 | 0.050 |
Why?
|
| Genomics | 2 | 2024 | 2835 | 0.050 |
Why?
|
| Anal Canal | 1 | 2022 | 236 | 0.050 |
Why?
|
| Cellular Microenvironment | 1 | 2020 | 36 | 0.050 |
Why?
|
| Fluocinonide | 1 | 2020 | 6 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2023 | 1121 | 0.050 |
Why?
|
| Inflammation | 1 | 2010 | 2518 | 0.050 |
Why?
|
| Keratolytic Agents | 1 | 2020 | 20 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2020 | 24 | 0.050 |
Why?
|
| Clobetasol | 1 | 2020 | 9 | 0.040 |
Why?
|
| Awareness | 1 | 2021 | 115 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2023 | 766 | 0.040 |
Why?
|
| WT1 Proteins | 1 | 2020 | 107 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2021 | 294 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 263 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 161 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 232 | 0.040 |
Why?
|
| Hyperpigmentation | 1 | 2020 | 34 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2022 | 283 | 0.040 |
Why?
|
| Dermatitis | 1 | 2020 | 61 | 0.040 |
Why?
|
| S100 Proteins | 1 | 2020 | 186 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2928 | 0.040 |
Why?
|
| Apoptosis | 1 | 2014 | 7757 | 0.040 |
Why?
|
| Vimentin | 1 | 2020 | 252 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2020 | 258 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 763 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 683 | 0.040 |
Why?
|
| Metronidazole | 1 | 2020 | 171 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2023 | 5438 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 95 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 252 | 0.040 |
Why?
|
| Adenoma | 1 | 2024 | 740 | 0.040 |
Why?
|
| Back | 1 | 2018 | 49 | 0.040 |
Why?
|
| Cathelicidins | 1 | 2018 | 25 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 797 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 15 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 323 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2018 | 153 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6177 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 657 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1470 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 411 | 0.040 |
Why?
|
| Dermis | 1 | 2017 | 63 | 0.030 |
Why?
|
| Survival Rate | 2 | 2021 | 12541 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2017 | 57 | 0.030 |
Why?
|
| Esophageal Neoplasms | 2 | 2021 | 3240 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2017 | 173 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 676 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 533 | 0.030 |
Why?
|
| Azure Stains | 1 | 2016 | 13 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 518 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 999 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 451 | 0.030 |
Why?
|
| Hemangioma | 1 | 2018 | 157 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1166 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2020 | 617 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 2016 | 90 | 0.030 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2016 | 72 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 190 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2016 | 94 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2020 | 1140 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2016 | 220 | 0.030 |
Why?
|
| Mastectomy | 1 | 2022 | 1553 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 622 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2016 | 320 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1049 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 686 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 298 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 329 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 427 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 2016 | 248 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 1424 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2828 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2019 | 502 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 2271 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2017 | 209 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2019 | 504 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2016 | 413 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2017 | 360 | 0.030 |
Why?
|
| Mitosis | 1 | 2016 | 681 | 0.030 |
Why?
|
| Piperidines | 1 | 2019 | 1100 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 660 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 678 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 4328 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2023 | 6390 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2017 | 847 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1726 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 4000 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 2027 | 0.020 |
Why?
|
| Biomarkers | 2 | 2016 | 5051 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2023 | 5149 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4492 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2017 | 1624 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3476 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1402 | 0.020 |
Why?
|
| Brain | 1 | 2023 | 4208 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 5002 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 5056 | 0.020 |
Why?
|
| Organelle Size | 1 | 2009 | 1 | 0.020 |
Why?
|
| Sarcoma | 1 | 2021 | 1839 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2021 | 9292 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2025 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2017 | 2441 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 9039 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2009 | 155 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2009 | 189 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 2008 | 19 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3444 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 2197 | 0.020 |
Why?
|
| Culture Media | 1 | 2008 | 344 | 0.020 |
Why?
|
| Keratins | 1 | 2008 | 340 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2359 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 6224 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 1063 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 575 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2008 | 1076 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 5574 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 1712 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4795 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 3117 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5776 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2020 | 12103 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 2196 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 1578 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 9042 | 0.010 |
Why?
|